Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 15/20 | 0.67 |
| ▸ | DRD2 | P14416 | 14/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 13/20 | 0.67 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8228863 | 0.88 | DRD2 (0.76) | DRD3DRD2ADRA1AHTR2AHTR2C | |
| SCHEMBL4925163 | 0.87 | DRD3 (0.67) | DRD3DRD2ADRA1AFAAHHRH4 | |
| SCHEMBL4928933 | 0.86 | ADRA1A (0.61) | DRD3DRD2ADRA1AHTR1AHRH4 | |
| SCHEMBL4932348 | 0.81 | DRD2 (1.00) | DRD3DRD2ADRA1AHTR2AHTR2C | |
| SCHEMBL4933086 | 0.80 | DRD2 (1.00) | DRD3DRD2ADRA1AFAAHHTR2A | |
| SCHEMBL5181188 | 0.80 | DRD2 (0.69) | DRD3DRD2ADRA1AFAAHHTR2A | |
| Hydrochloric Acid SCHEMBL4935249 | 0.79 | DRD2 (0.68) | DRD3DRD2ADRA1AFAAHHTR2A | |
| SCHEMBL5113647 | 0.78 | DRD2 (0.75) | DRD3DRD2ADRA1AHTR2AHTR1A | |
| SCHEMBL8225430 | 0.76 | DRD2 (0.78) | DRD3DRD2ADRA1AHTR2AHTR2C | |
| SCHEMBL4932306 | 0.76 | DRD2 (0.75) | DRD3DRD2ADRA1AHTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| EP-1659112-B1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET SOC CIV (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1659112-B1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET SOC CIV (FR) | 2007-06-20 | — | — | EP | disclosed |
| EP-1659112-A1 | Arylpiperazuine derivatives as selective ligand for the dopamine D3 receptor | BIOPROJET (FR) | 2006-05-24 | — | — | EP | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | DRD2, HTR2C, DRD3 | DRD3 3/4885DRD2 1/4885ADRA1A 93/4885 |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | CYP4Z1, CYP3A5, CYP1A2 | DRD3 1872/4885DRD2 1280/4885ADRA1A 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.